Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CPT1A | P50416 | 8/20 | 0.36 |
| ▸ | CPT1B | Q92523 | 5/20 | 0.36 |
| ▸ | CPT2 | P23786 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15021710 | 1.00 | S1PR1 (0.40) | S1PR1KMT2ACPT1ACPT1BCPT2 | |
| SCHEMBL2229703 | 0.95 | S1PR1 (0.42) | S1PR1KMT2ACPT1ACPT1BCPT2 | |
| SCHEMBL15021696 | 0.95 | S1PR1 (0.42) | S1PR1KMT2ACPT1ACPT1BCPT2 | |
| SCHEMBL2229532 | 0.92 | S1PR1 (0.40) | S1PR1KMT2ACPT1ACPT1BCPT2 | |
| SCHEMBL2229203 | 0.90 | S1PR1 (0.51) | S1PR1KMT2ACPT1ACPT1BCPT2 | |
| SCHEMBL15021694 | 0.90 | S1PR1 (0.51) | S1PR1KMT2ACPT1ACPT1BCPT2 | |
| SCHEMBL15021796 | 0.88 | S1PR1 (0.38) | S1PR1KMT2AMEN1L3MBTL1 | |
| SCHEMBL2226920 | 0.88 | S1PR1 (0.38) | S1PR1KMT2AMEN1L3MBTL1 | |
| SCHEMBL15021634 | 0.87 | KMT2A (0.38) | S1PR1KMT2ACPT1ACPT2L3MBTL1 | |
| SCHEMBL2226615 | 0.87 | KMT2A (0.38) | S1PR1KMT2ACPT1ACPT2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846691-B2 | Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | claimed |
| EP-2523959-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-11-27 | — | — | EP | claimed |
| US-20130158051-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-06-20 | — | — | US | claimed |
| EP-2523959-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2012-11-21 | — | — | EP | claimed |
| WO-2011086078-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | claimed |
| US-8846691-B2 | Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| EP-2523959-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-11-27 | — | — | EP | disclosed |
| US-20130158051-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158051-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | OXGR1, DPYD, FGF2 | S1PR1 2691/4885KMT2A 2818/4885CPT1A 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.